For High-Definition, Click
The AUA announced their guidelines for the treatment of men with castration-resistant prostate cancer (CRPC) in May of 2013 at their Annual Meeting. This guideline outlines the optimal management of six index patients across a variety of disease settings ranging from M0 CRPC to progressive disease, notes Neal D. Shore, MD (See slide in video for further description).
The therapeutic recommendations within the guideline were based on the level of published evidence available, with level A representing the strongest level of support. Based on the accumulation of additional data, AUA has recently added treatment with radium-223 to the guideline for men with bone metastatic CRPC, notes Shore.